Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05475210 · ClinicalTrials.gov registry record · Phase 1
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
A Phase 1 study of Neuroendocrine Tumors, sponsored by Molecular Targeting Technologies.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT05475210 is a Phase 1 study of Neuroendocrine Tumors that is actively recruiting participants, run by Molecular Targeting Technologies. The registered enrollment target is 9 participants, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05475210, a Phase 1 study of Neuroendocrine Tumors, is actively recruiting participants, sponsored by Molecular Targeting Technologies.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs.
Conditions Studied
Interventions
- DRUG 177Lu-DOTA-EB-TATE
- OTHER Amino Acid Solution
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-06-18 |
| Est. Completion | 2025-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05475210
The ClinicalTrials.gov registry entry for NCT05475210 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (95% lower). The listed sponsor is Molecular Targeting Technologies, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 2 interventions - of which 177Lu-DOTA-EB-TATE is the first listed.
NCT05475210 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05475210 about?
NCT05475210 is a clinical study titled "177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors". This is a Phase I clinical trial to assess the safety and dosimetry profiles of 177Lu-DOTA-EB-TATE in patients with advanced, metastatic or inoperable, somatostatin receptor-positive, well-differentiated GEP-NETs.
What is the current status of trial NCT05475210?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-06-18. Estimated completion is 2025-03-30.
What conditions does trial NCT05475210 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT05475210?
The interventions under investigation include: 177Lu-DOTA-EB-TATE (DRUG), Amino Acid Solution (OTHER).
Who is sponsoring clinical trial NCT05475210?
This trial is sponsored by Molecular Targeting Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05475210 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.